Larvol Delta - ADC-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Updates

ADCT-212 - ADC Therapeutics

epratuzumab-cys-tesirine (ADCT-602) - Overland ADCT BioPharma

ADCT-701 - ADC Therapeutics

https://www.businesswire.com/news/home/20230228005143/en/ADC-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results-and-Provides-Business-Updates

Feb 28, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next